BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 36.3% from the November 15th total of 1,350,000 shares. Based on an average daily trading volume, of 5,810,000 shares, the short-interest ratio is presently 0.3 days.

BioVie Stock Performance

BIVI traded up $0.05 during midday trading on Friday, hitting $2.64. The stock had a trading volume of 1,850,809 shares, compared to its average volume of 1,685,683. BioVie has a 1 year low of $1.04 and a 1 year high of $33.10. The business has a fifty day moving average of $2.54 and a 200 day moving average of $1.78. The company has a market cap of $46.91 million, a P/E ratio of -0.23 and a beta of 0.40.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings data on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.